D-0016-2021 Class II Terminated
FDA drug recall D-0016-2021 was initiated by Direct Rx on Jan 15, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is terminated (terminated Dec 7, 2020). Affected quantity: a) 54 bottles; b) 26 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 14, 2020
- Initiation Date
- Jan 15, 2020
- Termination Date
- Dec 7, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 54 bottles; b) 26 bottles
Product description
Ranitidine 150 mg, a) 60 Tabs (NDC 61919-339-60); and b) 90 Tabs (NDC 61919-339-90) bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534
Reason for recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Distribution pattern
FL, GA
Code information
Lots: a) 09AU1911 Exp. 02/28/2022; b) 09SE1904 Exp. 03/31/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0016-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026